Romanian stock indices close mixed in higher turnover
Bulgarian stock indices retreat amid higher turnover
Bulgaria to collect 2.1 bln euro for energy security fund in 2023
OECD downgrades Slovenia's 2023 GDP growth f'cast to 1.4%
Rompetrol Rafinare invests $6.5 mln in storage tanks overhaul
Nov 06, 2017 14:56 EEST
November 6 (SeeNews) - Bulgarian drug distributor Sopharma Trading [BUL:SO5] expects sales revenues from Serbian operations to double in the next three years, the company CEO has said.
The level of maturity of the Serbian market is a prerequisite for achieving high growth rates, Sopharma Trading CEO Dimitar Dimitrov said in a statement published by parent company Sopharma [BUL:3JR].
Sopharma Trading total consolidated revenues increased to 326.7 million levs ($193.8 million/167 million euro) in the first six months of 2017, from 297.4 million levs in the January-June preiod of the previous year. The company did not provide breakdown by country data.
Dimitrov added that each of the company's pharmacy stores, operating under the brand SOpharmacy, is performing above the market average.
In October, the company opened its 26th pharmacy in Bulgaria, in the town of Petrich.
In June, the Bulgarian competition authority said that Sopharma Trading plans to acquire control of 19 pharmacies. At the time the company operated 16 pharmacies in the country.
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options